These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 29936718)

  • 21. Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance.
    Verma D; Kantarjian HM; Jones D; Luthra R; Borthakur G; Verstovsek S; Rios MB; Cortes J
    Blood; 2009 Sep; 114(11):2232-5. PubMed ID: 19531657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
    Cortes JE; Gambacorti-Passerini C; Deininger MW; Mauro MJ; Chuah C; Kim DW; Dyagil I; Glushko N; Milojkovic D; le Coutre P; Garcia-Gutierrez V; Reilly L; Jeynes-Ellis A; Leip E; Bardy-Bouxin N; Hochhaus A; Brümmendorf TH
    J Clin Oncol; 2018 Jan; 36(3):231-237. PubMed ID: 29091516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL Transcript Level as Compared to LDH and Uric Acid Among Chronic Myeloid Leukemic Patients.
    Hailemariam TS; Mehdi M; Kinde S; Seifu D; Edao A
    Recent Pat Anticancer Drug Discov; 2021; 16(3):445-455. PubMed ID: 33618649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
    Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Atypical BCR-ABL transcripts in patients with chronic myeloid leukemia--the scheme for the diagnosis and monitoring of minimal residual disease].
    Link-Lenczowska D; Sacha T; Zawada M; Czekalska S; Florek I; Skotnicki AB
    Przegl Lek; 2014; 71(5):258-62. PubMed ID: 25248240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
    Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
    Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India.
    Anand MS; Varma N; Varma S; Rana KS; Malhotra P
    Indian J Med Res; 2012; 135(1):42-8. PubMed ID: 22382182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].
    Rosas-Cabral A; Martínez-Mancilla M; Ayala-Sánchez M; Vela-Ojeda J; Bahena-Reséndiz P; Vadillo-Buenfil M; Aviña-Zubieta JA; Salazar-Exaire D; Miranda-Peralta E; Marroquín A; Longoria-Revilla E
    Gac Med Mex; 2003; 139(6):553-9. PubMed ID: 14723051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution of
    Owojuyigbe TO; Durosinmi MA; Bolarinwa RAA; Salawu L; Akinola NO; Ademosun AA; Bosede OT
    Indian J Hematol Blood Transfus; 2020 Oct; 36(4):646-651. PubMed ID: 33100706
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The prognostic importance of BCR-ABL transcripts in Chronic Myeloid Leukemia: A systematic review and meta-analysis.
    Ghalesardi OK; Khosravi A; Azizi E; Ahmadi SE; Hajifathali A; Bonakchi H; Shahidi M
    Leuk Res; 2021 Feb; 101():106512. PubMed ID: 33524640
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the Major BCR-ABL1 Transcript Type on Clinical and Biological Parameters and Molecular Response in Patients With Chronic Myeloid Leukemia.
    Nachi M; Kihel I; Entasoltane B; Brahimi M; Yafour N; Guella D; Abed A; Bekadja MA
    Hematol Oncol Stem Cell Ther; 2022 Jun; 15(2):58-62. PubMed ID: 32971032
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia with e14a3 BCR-ABL transcript: analysis of characteristics and prognostic significance.
    Gui X; Zhang Y; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
    Leuk Lymphoma; 2015; 56(12):3343-7. PubMed ID: 25962435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel e8a2 BCR-ABL transcript variant.
    Qin YZ; Jiang B; Jiang Q; Zhang Y; Jiang H; Li JL; Zhu HH; Li LD; Liu YR; Chen SS; Huang XJ
    Acta Haematol; 2008; 120(3):146-9. PubMed ID: 19039205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of BCR-ABL fusion transcripts in Iranian patients with chronic myeloid leukemia.
    Yaghmaie M; Ghaffari SH; Ghavamzadeh A; Alimoghaddam K; Jahani M; Mousavi SA; Irvani M; Bahar B; Bibordi I
    Arch Iran Med; 2008 May; 11(3):247-51. PubMed ID: 18426313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential molecular response of the transcripts B2A2 and B3A2 to imatinib mesylate in chronic myeloid leukemia.
    de Lemos JA; de Oliveira CM; Scerni AC; Bentes AQ; Beltrão AC; Bentes IR; Azevedo TC; Maradei-Pereira LM
    Genet Mol Res; 2005 Dec; 4(4):803-11. PubMed ID: 16475128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the clinico-hematological relevance of the breakpoint location within M-BCR in chronic myeloid leukemia.
    Bennour A; Ouahchi I; Achour B; Zaier M; Youssef YB; Khelif A; Saad A; Sennana H
    Med Oncol; 2013 Mar; 30(1):348. PubMed ID: 23269583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.
    Hardling M; Wei Y; Palmqvist L; Swolin B; Stockelberg D; Gustavsson B; Ekeland-Sjöberg K; Wadenvik H; Ricksten A
    Med Oncol; 2004; 21(4):349-58. PubMed ID: 15579919
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR/ABL p210, p190 and p230 fusion genes in 250 Mexican patients with chronic myeloid leukaemia (CML).
    Arana-Trejo RM; Ruíz Sánchez E; Ignacio-Ibarra G; Báez de la Fuente E; Garces O; Gómez Morales E; Castro Granados M; Ovilla Martínez R; Rubio-Borja ME; Solís Anaya L; Herrera P; Delgado Llamas J; Kofman S
    Clin Lab Haematol; 2002 Jun; 24(3):145-50. PubMed ID: 12067277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.